Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).
The protein has a calculated MW of 9.6 kDa. The protein migrates as 15-17 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
>90% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Biotinylated Human BCMA, His,Avitag, premium grade on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).
The purity of Biotinylated Human BCMA, His,Avitag, premium grade (Cat. No. BCA-H82E4) was greater than 85% as determined by SEC-HPLC.
2e5 of anti-BCMA CAR-293 cells were stained with 100 μL of 1 μg/mL of Biotinylated Human BCMA, His,Avitag, premium grade (Cat. No. BCA-H82E4) and negative control protein respectively, washed and then followed by PE-SA and analyzed with FACS (QC tested).
Immobilized Human BAFF, Fc Tag, active trimer (Cat. No. BAF-H5261) at 5 μg/mL (100 μL/well) can bind Biotinylated Human BCMA, His,Avitag, premium grade (Cat. No. BCA-H82E4) with a linear range of 0.01-0.313 μg/mL (QC tested).
Immobilized Anti-Human BCMA MAb at 2 μg/mL (100 μL/well) can bind Biotinylated Human BCMA, His,Avitag, premium grade (Cat. No. BCA-H82E4) with a linear range of 0.5-8 ng/mL (Routinely tested).
Immobilized Human APRIL, Fc Tag at 5 μg/mL (100 μL/well) can bind Biotinylated Human BCMA, His,Avitag, premium grade (Cat. No. BCA-H82E4) with a linear range of 0.6-20 ng/mL (Routinely tested).
Loaded Human BAFF Protein, Fc Tag (Cat. No. BAF-H5261) on Protein A Biosensor, can bind Biotinylated Human BCMA, His,Avitag, premium grade (Cat. No. BCA-H82E4) with an affinity constant of 0.55 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Price(USD) : $350.00
Price(USD) : $1520.00
Price(USD) : $32.00
Price(USD) : $137.00
Price(USD) : $50.00
Price(USD) : $120.00
Price(USD) : $138.00
Price(USD) : $230.00
Emerging VoCs, Omicron, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
CD3 proteins and a collection of for bispecific antibody development which are of high specificity and bioactivities and suitable for immunization, antibody screening.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
The MABSOL biotinylated protein collection includes more than a hundred commonly studied drug targets and biomarker proteins.
Comprehensive cytokines including IL families, growth factors, chemokines, TNFs, etc. These products are HEK293 expressed and nearly in authentic structure, high purity and bioactivity, cell based assay/SPR/BLI verified.
To support preclinical/clinical immunogenicity and PK analysis, ACROBiosystems has developed a series of high-affinity anti-idiotypic antibodies. Our pipeline covers five hot targets including adalimum*b, rituxim*b, cetuxim*b, trastuzum*b, and bevacizum*b.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Idecabtagene vicleucel | bb-2121 | Approved | Bluebird Bio Inc | Abecma | Japan | Multiple Myeloma | Bristol-Myers Squibb Kk | 2021-03-26 | Multiple Myeloma | Details |
Teclistamab | JNJ-64007957; JNJ-64007959; JNJ-7957 | Approved | Genmab A/S, Janssen Global Services Llc | TECAYLI | United States | Multiple Myeloma | Janssen Biotech Inc | 2022-08-23 | Hematologic Diseases; Hematologic Neoplasms; Smoldering Multiple Myeloma; Multiple Myeloma | Details |
Belantamab mafodotin | GSK-2857916; GSK2857916 | Approved | Glaxosmithkline Plc | BLENREP | EU | Multiple Myeloma | Glaxosmithkline (Ireland) Ltd | 2020-08-05 | Bone Marrow Neoplasms; Lymphoma, B-Cell; Immunoglobulin Light-chain Amyloidosis; Multiple Myeloma; Plasmablastic Lymphoma; Amyloidosis | Details |
Ciltacabtagene autoleucel | JNJ-4528; LCAR-B38M; JNJ-68284528 | Approved | Nanjing Legend Biotechnology Co Ltd | Carvykti | Japan | Multiple Myeloma | Nanjing Legend Biotechnology Co Ltd | 2022-02-28 | Multiple Myeloma | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
HBI-0101 | HBI-0101 | Phase 1 Clinical | Hadassah Medical Organization | Details | |
Anti-BCMA CAR T cell therapy (Wuhan Bio-Raid Biotechnology) | Clinical | Wuhan Bio-Raid Biotechnology | Hematologic Neoplasms | Details | |
BCMA CAR-T cell therapy (Hebei Senlang Biotechnology) | Clinical | Hebei Senlang Biological Technology Co Ltd | Multiple Myeloma | Details | |
Recombinant humanized anti-BCMA/CD3 bispecific antibody(New Time Pharmaceutical) | Phase 1 Clinical | Shandong New Time Pharmaceutical Co Ltd | Multiple Myeloma | Details | |
BCMA-NKE | BCMA-NKE | Phase 1 Clinical | Bristol-Myers Squibb Company | Multiple Myeloma | Details |
HY-027 | HY-027 | Phase 1 Clinical | Multiple Myeloma | Details | |
Anti-BCMA CAR T-cell therapy (Huazhong University of Science and Technology) | Clinical | Huazhong University Of Science And Technology | Multiple Myeloma | Details | |
Anti-BCMA anti-CD38 bispecific chimeric antigen receptor T cell therapy (Shengyan Pharmaceutical Technology) | Phase 1 Clinical | Wuhan Union Hospital, Shengyan Pharmaceutical Technology | Multiple Myeloma | Details | |
Ispectamab debotansine | CC-99712; BMS-986352; SP-8919 | Phase 1 Clinical | Celgene Corp | Multiple Myeloma | Details |
MCM-998 | MCM-998; LXG-250 | Phase 1 Clinical | Novartis Pharma Ag | Multiple Myeloma | Details |
BCMA-UCART cell therapy (Shanghai Bioray Laboratory) | Clinical | Multiple Myeloma | Details | ||
BCMA-PD1 CAR T cell therapy (General Hospital of the People's Liberation Army) | Phase 2 Clinical | People'S Liberation Army General Hospital Military Service | Multiple Myeloma | Details | |
Anti BCMA CART cell therapy (Shanghai YaKe Biotechnology) | Phase 1 Clinical | Shanghai YaKe Biotechnology Co Ltd | Multiple Myeloma | Details | |
Anti BCMA chimeric antigen receptor T cell therapy (Chongqing Precision Biotech) | Phase 2 Clinical | Chongqing Precision Biotechnology Co Ltd | Multiple Myeloma | Details | |
JWCAR129 | JWCAR129; JWCAR-129 | Phase 1 Clinical | Suzhou Yaomingjunuo Biotechnology Co Ltd | Multiple Myeloma | Details |
GR-1803 | GR-1803 | Phase 1 Clinical | Chongqing Zhixiang Jintai Biopharmaceutical Co Ltd, Zhixiang (Shanghai) Pharmaceutical Technology Co Ltd | Multiple Myeloma | Details |
Anti-BCMA CAR-T cell therapy (PersonGen Biomedicine) | Persongen Biotherapeutics | Details | |||
C-4-29 | Phase 1 Clinical | Chongqing Precision Biotechnology Co Ltd | Carcinoma, Renal Cell; Multiple Myeloma | Details | |
BCMA-targeted universal LCAR-BCX cell therapy (Nanjing Legend Biotech) | LCAR-BCX | Phase 1 Clinical | Multiple Myeloma | Details | |
CXCR4 modified anti-BCMA CAR T cell therapy (Sichuan University) | Phase 1 Clinical | Sichuan University | Multiple Myeloma | Details | |
EMB-06 | EMB-06; EMB06 | Phase 2 Clinical | Shanghai Epimab Biotherapeutics, Inc | Multiple Myeloma | Details |
Anti-BCMA CAR-NK Cell Therapy (Sichuan Kelun-Biotech) | Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | Details | |||
BCMA CAR-T Cell Therapy (Shenzhen University General Hospital) | Shenzhen University General Hospital | Details | |||
CAR-BCMA(Sheba Medical Center) | Phase 2 Clinical | Sheba Medical Center, Israel | Multiple Myeloma | Details | |
MEDI-2228 | MEDI-2228 | Medimmune Llc | Details | ||
ACLX-001 | ACLX-001 | Arcellx Inc | Details | ||
BCMA/CD19 CAR-T cell therapy (The First Affiliated Hospital of Nanchang University) | The First Affiliated Hospital Of Nanchang University | Details | |||
Alnuctamab | CC-93269; EM-901 | Celgene Corp | Details | ||
BCMA CAR-T cell therapy (Chongqing Precision Biotech) | Chongqing Precision Biotechnology Co Ltd | Details | |||
AMG-224 | AMG-224 | Amgen Inc | Details | ||
PBCAR-269A | PBCAR-269A | Precision Biosciences Inc | Details | ||
OriC-321 | OriC-321; Ori-C-321 | Phase 1 Clinical | Zhejiang University | Multiple Myeloma | Details |
ACTR 087/SEA BCMA combination therapy | Phase 1 Clinical | Unum Therapeutics Inc | Multiple Myeloma | Details | |
Orvacabtagene autoleucel | MCARH-171; ET-140; FCARH-143; ET140-CAR; JCARH-125 | Phase 2 Clinical | Multiple Myeloma | Details | |
REGN-5459 | REGN-5459 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Multiple Myeloma; Renal Insufficiency, Chronic | Details |
Anti-CD19+/BCMA CAR-T cells (Hrain Biotechnology) | Phase 1 Clinical | Hrain Biotechnology Co Ltd | POEMS Syndrome | Details | |
CART-BCMA | MTV-273; CART-BCMA | Phase 1 Clinical | University Of Pennsylvania | Multiple Myeloma | Details |
Azintuxizumab | TNB-383B; ABBV-383 | Phase 2 Clinical | Teneobio Inc, Abbvie Inc | Multiple Myeloma | Details |
Autologous BCMA-directed CAR T-cell therapy (The First Affiliated Hospital of Soochow University) | Phase 3 Clinical | The First Affiliated Hospital Of Soochow University | Leukemia; Multiple Myeloma | Details | |
SEA-BCMA | SEA-BCMA; SGN-BCMA | Phase 1 Clinical | Seattle Genetics Inc | Multiple Myeloma | Details |
CD19/BCMA-targeted CAR-T Cell Therapy (Zhejiang University) | Phase 1 Clinical | Zhejiang University | Nephritis; Sjogren's Syndrome; Scleroderma, Systemic; Autoimmune Diseases; Multiple Myeloma; Lupus Nephritis; Lupus Erythematosus, Systemic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details | |
BCMA Targeted CAR-T Cell Therapy (Yake Biotechnology) | CBG-002 CAR-T | Phase 1 Clinical | Shanghai YaKe Biotechnology Co Ltd | Multiple Myeloma | Details |
Anti-BCMA CAR-T cell therapy (Xinqiao Hospital) | Phase 1 Clinical | Multiple Myeloma | Details | ||
Humanized CART Directed Against BCMA | ARI-0002h | Phase 2 Clinical | Instituto De Salud Carlos Iii | Multiple Myeloma | Details |
MCARH-125 | MCARH-125 | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center | Multiple Myeloma | Details |
LCAR-B4822M | LCAR-B4822M | Phase 1 Clinical | Genscript Biotech Corp | Multiple Myeloma | Details |
HDP-101 | HDP-101; HDP101-ATAC | Phase 2 Clinical | Heidelberg | Paraproteinemias; Multiple Myeloma | Details |
BCMA-CS1 cCAR T cell therapy (iCell Gene Therapeutics) | Phase 1 Clinical | Multiple Myeloma | Details | ||
LUCAR-B68 cells Therapy(Nanjing Legend Biotech Co) | Phase 1 Clinical | Nanjing Legend Biotechnology Co Ltd | Multiple Myeloma | Details | |
FT-576 | FT-576 | Phase 1 Clinical | University Of Minnesota, Fate Therapeutics Inc | Bone Marrow Neoplasms; Multiple Myeloma | Details |
BCMA CAR-NK 92 cell therapy (Asclepius Technology Company Group) | Phase 2 Clinical | Asclepius Technology Company Group | Multiple Myeloma | Details | |
CC-98633 | CC-98633 | Phase 1 Clinical | Celgene Corp | Multiple Myeloma | Details |
Motacabtagene lurevgedleucel | CTX-120 | Phase 1 Clinical | Crispr Therapeutics Ag | Multiple Myeloma | Details |
Anti-BCMA/CD19 CAR-T Therapy(University College London) | Phase 1 Clinical | University College London | Multiple Myeloma | Details | |
AUTO-2 | AUTO-2; SUB-96123 | Phase 1 Clinical | Autolus | Multiple Myeloma | Details |
Pavurutamab | AMG-701 | Phase 1 Clinical | Amgen Inc | Multiple Myeloma | Details |
PHE-885 | PHE-885 | Phase 2 Clinical | Novartis Pharma Ag | Hematologic Neoplasms; Multiple Myeloma | Details |
CM-336(Connaught Biomedical Technology) | CM-336 | Phase 2 Clinical | Keymed Biosciences Co Ltd | Multiple Myeloma | Details |
BCMA-CD19 cCAR T cell therapy (iCell Gene Therapeutics) | Phase 1 Clinical | Icell Gene Therapeutics (Int'L) Ltd | Multiple Myeloma; Lupus Erythematosus, Systemic | Details | |
Anti-BCMA chimeric antigen receptor T cell therapy (Cartesian) | Descartes-08 | Phase 2 Clinical | Cartesian Therapeutics Inc | Myasthenia Gravis; Multiple Myeloma | Details |
Anti-BCMA CAR T-cell therapy (Actavis/Eugia Pharma) | Phase 1 Clinical | Eugia Pharma Specialities Ltd, Actavis Inc | Multiple Myeloma | Details | |
F-182112 | F-182112; F182112 | Phase 1 Clinical | Shandong New Time Pharmaceutical Co Ltd | Multiple Myeloma | Details |
WVT-078(Novartis Pharma) | WVT-078 | Phase 1 Clinical | Novartis Pharma Ag | Multiple Myeloma | Details |
Anti BCMA CAR T cell therapy (Shanghai Hrain Biotechnology) | BCMA-CART | Phase 2 Clinical | Hrain Biotechnology Co Ltd | Multiple Myeloma | Details |
Autologous anti-BCMA/GPRC5D CAR-T cell therapy (Xuzhou Medical University) | Phase 2 Clinical | Xuzhou Medical University (Xzmu) | Multiple Myeloma | Details | |
GC-012F | GC-012F | Phase 2 Clinical | Gracell Biotechnologies (Shanghai) Co Ltd | Multiple Myeloma; Lymphoma, Non-Hodgkin | Details |
Descartes-11 | Descartes-11; Descartes-011 | Phase 2 Clinical | Cartesian Therapeutics Inc | Multiple Myeloma | Details |
Anti-BCMA CAR T-cell therapy (Arcellx) | CART-ddBCMA | Phase 2 Clinical | Arcellx Inc | Multiple Myeloma | Details |
IBI-346 | IBI-346 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Multiple Myeloma | Details |
C-CAR088 | C-CAR088 | Phase 2 Clinical | Cellular Biomedicine (Shanghai) Co Ltd | Multiple Myeloma | Details |
Elranatamab | PF-06863135 | Phase 3 Clinical | Pfizer Pharmaceuticals Ltd (China) | Bone Marrow Neoplasms; Multiple Myeloma | Details |
ALLO-605 | ALLO-605; ALLO605 | Phase 2 Clinical | Allogene Therapeutics Inc | Multiple Myeloma | Details |
Linvoseltamab | REGN-5458 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Multiple Myeloma; Renal Insufficiency, Chronic | Details |
ALLO-715 | ALLO-715 | Phase 1 Clinical | Allogene Therapeutics Inc, Cellectis Sa | Multiple Myeloma | Details |
Pacanalotamab | AMG-420; BI-836909 | Phase 1 Clinical | Micromet Inc | Multiple Myeloma | Details |
bb-21217 | bb-21217 | Phase 1 Clinical | Bluebird Bio Inc, Bristol-Myers Squibb Company | Multiple Myeloma | Details |
BCMA CAR-T Cells (Pregene) | PRG-1801 | Phase 1 Clinical | Shenzhen Prekin Biopharmaceutical Co Ltd | Multiple Myeloma | Details |
BCMA TriTAC | HPN-217 | Phase 1 Clinical | Harpoon Therapeutics, Abbvie Inc | Multiple Myeloma | Details |
This web search service is supported by Google Inc.